Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight – Has The Bull Case Changed?

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500.
• The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s New Drug Application in China highlight Kelun-Biotech’s transition from an early-stage ADC platform story toward a broader, clinically validated oncology portfolio with potential regulatory and commercial milestones.
• We’ll now examine how these ASCO results, particularly the progression-free survival benefit from sacituzumab tirumotecan plus pembrolizumab, may reshape Kelun-Biotech’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

To own Kelun-Biotech, you need to believe its ADC and targeted oncology pipeline can translate expanding clinical validation into approvals, broader reimbursement and, over time, a more self-sustaining revenue mix. The ASCO data for sacituzumab tirumotecan plus pembrolizumab and lunbotinib reinforce the near term regulatory opportunity in NSCLC, while the key risk remains that late stage programs or reviews underperform expectations and leave the company reliant on volatile partnership income.

Among the recent announcements, the NMPA’s acceptance of the New Drug Application for lunbotinib fumarate in RET fusion positive NSCLC looks especially relevant, because it turns strong Phase II data into a concrete regulatory catalyst in China that sits alongside sacituzumab tirumotecan’s Lancet publication and first line NSCLC readout as investors weigh how quickly Kelun-Biotech can shift from clinical promise to broader commercial uptake.

Yet investors should also be aware that if these oncology filings face delays or setbacks, the risk to Kelun-Biotech’s path to…

Read the full narrative on Sichuan Kelun-Biotech Biopharmaceutical (it’s free!)

Sichuan Kelun-Biotech Biopharmaceutical’s narrative projects CN¥6.9 billion revenue and CN¥1.6 billion earnings by 2029. This requires 49.5% yearly revenue growth and about a CN¥2.0 billion earnings increase from -CN¥382.0 million today.

Uncover how Sichuan Kelun-Biotech Biopharmaceutical’s forecasts yield a HK$533.85 fair value, a 36% upside to its current price.

Two fair value estimates from the Simply Wall St Community span roughly HK$534 to HK$886 per share, indicating a wide spread in expectations. Against that backdrop, the recent ASCO readouts and pending NSCLC filings could be pivotal for how you and other investors think about Kelun-Biotech’s ability to convert its oncology pipeline into a more balanced mix of self commercialized revenue and partnership income.

Explore 2 other fair value estimates on Sichuan Kelun-Biotech Biopharmaceutical – why the stock might be worth just HK$533.85!

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
• A great starting point for your Sichuan Kelun-Biotech Biopharmaceutical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Sichuan Kelun-Biotech Biopharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Sichuan Kelun-Biotech Biopharmaceutical’s overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com…Read more by Simply Wall St